Davis Hugh M. 4

What Happened

• Hugh M. Davis, President and COO (and Director) of Aclaris Therapeutics, received two grants of restricted stock units (RSUs) on Feb 2, 2026: 96,100 RSUs and 336,300 RSUs, for a total of 432,400 RSUs. The awards were granted at $0.00 (no cash paid) and are reported as derivative securities (contingent rights to common stock).

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-06 (Period of Report: 2026-02-02). No late-filing flag provided in the supplied data.
• Award amounts/prices: 96,100 RSUs @ $0.00 and 336,300 RSUs @ $0.00 (total 432,400 RSUs).
• What the derivatives mean: Each RSU is a contingent right to receive one share of common stock upon vesting (Footnote F1).
• Vesting: The RSUs vest in four equal annual installments on the 1st, 2nd, 3rd and 4th anniversaries of Feb 2, 2026, subject to continuous service (Footnote F2).
• Additional note: Footnote F3 describes a 25%/4-year style vesting schedule applicable to option awards (included in the filing).
• Shares owned after transaction: Not specified in the information provided here — see the full Form 4 for post-transaction holdings.

Context

• These were compensation awards (RSUs), not open-market purchases or sales. Awards do not require an immediate cash outlay and do not represent an immediate bullish or bearish trade by the insider; they are typical executive compensation that can dilute outstanding shares if/when settled.
• Vesting is service-based; shares will only be issued if vesting conditions (continuous service) are met on each anniversary.